Hematology and Oncology, MD Anderson Cancer Center.
Treatment for non-small cell lung cancer has been improving, with personalized treatment increasingly becoming a reality in the clinic. Unfortunately, these advances have largely been confined to the treatment of adenocarcinomas. Treatment options for squamous cell carcinoma of the lung have lagged behind, partly due to a lack of understanding of the oncogenes driving squamous cell carcinoma. Cytotoxic chemotherapy continues to be the only treatment option for many of our patients, and there are no genetic tests that are clinically useful for patients with squamous cell carcinoma. Recent basic science advances have identified mutations and alterations in protein expression frequently found in squamous cell carcinomas, and clinical trials are ongoing to target these changes.